Welcome to our dedicated page for Medexus Pharmace news (Ticker: MEDXF), a resource for investors and traders seeking the latest updates and insights on Medexus Pharmace stock.
Medexus Pharmace (MEDXF) is a North American specialty pharmaceutical leader focused on innovative therapies for complex conditions in oncology, hematology, and rheumatology. This page provides investors and healthcare professionals with essential updates on the company's latest developments.
Access timely press releases covering regulatory milestones, product launches, financial results, and strategic partnerships. Our curated news collection helps stakeholders track MEDXF's progress in commercializing treatments for rare diseases and autoimmune disorders.
Key updates include FDA/Health Canada submissions, licensing agreements, clinical trial developments, and market expansion initiatives. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for direct access to MEDXF's official announcements and analysis of its growing role in specialty pharmaceuticals. Check regularly for updates demonstrating the company's commitment to addressing unmet medical needs through targeted therapeutic solutions.
Medexus Pharmaceuticals reported financial results for Q4 and fiscal year 2021, with revenue reaching $79.7 million, a 43.5% increase from the prior year. Q4 revenue was $17.6 million, a decline from $18.8 million due to IXINITY® sales reduction. The company posted a net loss of $10.5 million in Q4 and $28.3 million for the year. As of March 31, 2021, cash and cash equivalents totaled $18.7 million. The firm emphasizes growth in the U.S. market driven by the licensing of treosulfan, with a PDUFA date on August 11, 2021.
Medexus Pharmaceuticals announced the final approval for its common shares to list on the Toronto Stock Exchange (TSX), with trading set to begin on June 17, 2021. This upgrade from the TSX Venture Exchange aims to enhance the company’s profile and liquidity, attracting a wider range of institutional investors. The company also confirmed that its previous plans for a Nasdaq listing are postponed but remain a future goal. Alongside common shares, convertible debentures and warrants will also transition to TSX.
Medexus Pharmaceuticals Inc. (TSXV: MDP, OTCQX: MEDXF) will present at the Raymond James Human Health Innovation Conference on June 21, 2021, at 2:40 PM ET. CEO Ken d’Entremont and CFO Roland Boivin will provide a company overview and business update, which will be available for live webcast and replay on the company's website. The management team will also engage in virtual one-on-one meetings throughout the conference. Medexus focuses on innovative products for rare diseases, with key products including Rasuvo™, IXINITY®, and Rupall®.
Medexus Pharmaceuticals Inc. (TSXV: MDP, OTCQX: MEDXF) will host a conference call on June 17, 2021, at 8:00 AM ET to discuss its financial results for the fiscal year ended March 31, 2021. Financial statements and MD&A will be filed post-market on June 16, 2021. The call can be accessed via telephone or through a webcast. Medexus focuses on innovative rare disease treatments, including Rasuvo™, IXINITY®, and Rupall®, and aims to advance its portfolio to support growth over the next decade.
Medexus Pharmaceuticals has expanded its medical affairs team in anticipation of launching treosulfan, an innovative agent for patients receiving allo-HSCT. This proactive measure aims to ensure a successful launch by the scheduled PDUFA date in August 2021. Treosulfan, which showed a 64.0% two-year event-free survival rate in clinical trials, is projected to become the new standard of care, filling a significant market gap. The team includes experienced leaders like Keith Steward and J. Lynn Bass, enhancing Medexus's capability to engage with key stakeholders.
Medexus Pharmaceuticals (MEDXF) has announced the immediate availability of Triamcinolone Hexacetonide (TH) Injectable Suspension in the U.S. through the FDA’s Drug Shortage program. This drug is indicated for treating various inflammatory joint diseases. Medexus is collaborating with Ethypharm to expedite the data necessary for filing an Abbreviated New Drug Application (ANDA). The company aims to establish a solid portfolio in rare diseases, focusing on innovative healthcare products and expanding its commercial presence across North America.
Medexus Pharmaceuticals, listed as OTCQX: MEDXF, announced their participation in the LD Micro Invitational XI investor conference from June 8-10, 2021. CEO Ken d’Entremont and CFO Roland Boivin will present on June 8 at 12:30 p.m. EST. The conference provides a platform for investors to gain insights into Medexus's growth strategy in the rare disease market. Medexus focuses on innovative therapies for auto-immune diseases, hematology, and allergies, with prominent products like Rasuvo™, IXINITY®, and Rupall®.
Medexus Pharmaceuticals announced its participation in the Sidoti & Company Virtual Microcap Conference from May 19 to May 20, 2021. CEO Ken d’Entremont and CFO Roland Boivin will present on May 19 at 9:15 AM Eastern Time, with a live webcast available for replay. The company will also hold one-on-one virtual meetings with interested investors. Medexus focuses on innovative and rare disease treatments, particularly in auto-immune disease, hematology, and allergy, featuring products like Rasuvo™ and IXINITY®.
Medexus Pharmaceuticals announced participation in upcoming investor conferences, including the Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, and the Stifel 2021 Canada Cross Sector Insight Conference on April 21, 2021. CEO Ken d’Entremont and CFO Roland Boivin will present corporate updates to engage with investors. Medexus focuses on innovative treatments for rare diseases, providing products like Rasuvo™ and IXINITY® for auto-immune diseases and hemophilia. The company aims to enhance its market presence and investor relationships through these events.
Medexus Pharmaceuticals has announced that all non-executive directors will receive restricted share units (RSUs) instead of cash fees for 2021. This decision aligns with the Company’s 2018 omnibus equity incentive plan. The RSUs will vest immediately, allowing directors to acquire common shares at $0.01 each. Medexus focuses on developing innovative products for rare diseases, particularly in auto-immune diseases and hematology, with notable products like Rasuvo™ and IXINITY®. The Company's strategic move to offer RSUs may enhance alignment with shareholder interests.
FAQ
What is the current stock price of Medexus Pharmace (MEDXF)?
What is the market cap of Medexus Pharmace (MEDXF)?
